Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Atorvastatin and Caffeine in Combination Regulates Apoptosis, Migration, Invasion and Tumorspheres of Prostate Cancer Cells.

Wang Z, Zhang L, Wan Z, He Y, Huang H, Xiang H, Wu X, Zhang K, Liu Y, Goodin S, Du Z, Zheng X.

Pathol Oncol Res. 2018 May 24. doi: 10.1007/s12253-018-0415-7. [Epub ahead of print]

PMID:
29796873
2.

Pharmacists' critical role in cancer clinical trials.

Goodin S.

Am J Health Syst Pharm. 2018 May 15;75(10):592-593. doi: 10.2146/ajhp180038. No abstract available.

PMID:
29748294
3.

Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgen-independent growth of prostate cancer cells.

Huang H, He Y, Zhang L, Xiang H, Li D, Liu W, Xu XT, Goodin S, Zhang K, Zheng X.

Food Funct. 2018 Apr 25;9(4):2398-2408. doi: 10.1039/c7fo01983a.

PMID:
29595853
4.

Adaptation of Intestinal and Bile Acid Physiology Accompany the Metabolic Benefits Following Ileal Interposition in the Rat.

Zhao P, Wendt D, Goodin SZ, Ravichandran S, Chouinard TE, Strader AD.

Obes Surg. 2018 Mar;28(3):725-734. doi: 10.1007/s11695-017-2886-0.

5.

Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo.

Wang ZS, Huang HR, Zhang LY, Kim S, He Y, Li DL, Farischon C, Zhang K, Zheng X, Du ZY, Goodin S.

Biol Pharm Bull. 2017;40(8):1247-1254. doi: 10.1248/bpb.b17-00077.

6.

The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.

Yu L, Wu X, Chen M, Huang H, He Y, Wang H, Li D, Du Z, Zhang K, Goodin S, Zheng X.

Int J Med Sci. 2017 Apr 7;14(4):356-366. doi: 10.7150/ijms.18382. eCollection 2017.

7.

Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.

Huang H, Liu T, Guo J, Yu L, Wu X, He Y, Li D, Liu J, Zhang K, Zheng X, Goodin S.

Bioorg Med Chem Lett. 2017 Jun 1;27(11):2286-2291. doi: 10.1016/j.bmcl.2017.04.047. Epub 2017 Apr 17.

8.

Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells.

He Y, Huang H, Farischon C, Li D, Du Z, Zhang K, Zheng X, Goodin S.

Oncol Rep. 2017 Feb;37(2):953-960. doi: 10.3892/or.2017.5353. Epub 2017 Jan 4.

PMID:
28075470
9.

Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer.

Chen X, Liu Y, Wu J, Huang H, Du Z, Zhang K, Zhou D, Hung K, Goodin S, Zheng X.

Cancer Genomics Proteomics. 2016 Mar-Apr;13(2):151-60.

10.

Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.

Goodin S, Barbour S, Song J, Berrak E, Cox D.

Am J Health Syst Pharm. 2015 Dec 15;72(24):2150-6. doi: 10.2146/ajhp140773.

PMID:
26637514
11.

Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells.

Huang H, Chen X, Li D, He Y, Li Y, Du Z, Zhang K, DiPaola R, Goodin S, Zheng X.

PLoS One. 2015 Dec 2;10(12):e0144293. doi: 10.1371/journal.pone.0144293. eCollection 2015.

12.

A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.

Stein MN, Hussain M, Stadler WM, Liu G, Tereshchenko IV, Goodin S, Jeyamohan C, Kaufman HL, Mehnert J, DiPaola RS.

Clin Genitourin Cancer. 2016 Feb;14(1):22-7. doi: 10.1016/j.clgc.2015.09.010. Epub 2015 Sep 21.

13.

ASHP guidelines on preventing medication errors with chemotherapy and biotherapy.

Goldspiel B, Hoffman JM, Griffith NL, Goodin S, DeChristoforo R, Montello CM, Chase JL, Bartel S, Patel JT.

Am J Health Syst Pharm. 2015 Apr 15;72(8):e6-e35. doi: 10.2146/sp150001. No abstract available.

PMID:
25825193
14.

α-Tomatine inhibits growth and induces apoptosis in HL-60 human myeloid leukemia cells.

Huang H, Chen S, Van Doren J, Li D, Farichon C, He Y, Zhang Q, Zhang K, Conney AH, Goodin S, Du Z, Zheng X.

Mol Med Rep. 2015 Jun;11(6):4573-8. doi: 10.3892/mmr.2015.3238. Epub 2015 Jan 22.

15.

Potent inhibitory effect of δ-tocopherol on prostate cancer cells cultured in vitro and grown as xenograft tumors in vivo.

Huang H, He Y, Cui XX, Goodin S, Wang H, Du ZY, Li D, Zhang K, Tony Kong AN, DiPaola RS, Yang CS, Conney AH, Zheng X.

J Agric Food Chem. 2014 Nov 5;62(44):10752-8. doi: 10.1021/jf504058f. Epub 2014 Oct 27.

16.

Resolution of bilateral moyamoya associated collateral vessel aneurysms: Rationale for endovascular versus surgical intervention.

Amin-Hanjani S, Goodin S, Charbel FT, Alaraj A.

Surg Neurol Int. 2014 Jun 19;5(Suppl 4):S155-60. doi: 10.4103/2152-7806.134812. eCollection 2014.

17.

Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.

Huang H, Cui XX, Chen S, Goodin S, Liu Y, He Y, Li D, Wang H, Van Doren J, Dipaola RS, Conney AH, Zheng X.

Anticancer Res. 2014 Jul;34(7):3357-63.

18.

Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial.

Richie JP Jr, Das A, Calcagnotto AM, Sinha R, Neidig W, Liao J, Lengerich EJ, Berg A, Hartman TJ, Ciccarella A, Baker A, Kaag MG, Goodin S, DiPaola RS, El-Bayoumy K.

Cancer Prev Res (Phila). 2014 Aug;7(8):796-804. doi: 10.1158/1940-6207.CAPR-14-0042. Epub 2014 Jun 17.

19.

Augmentation of N-butyl cyanoacrylate embolization of cranial, head, and neck tumors by simultaneous infusion of 5% dextrose solution.

Alaraj A, Dashti R, Mehta NK, Goodin S, Charbel FT, Aletich VA.

J Neurointerv Surg. 2015 Jun;7(6):463-70. doi: 10.1136/neurintsurg-2013-011071. Epub 2014 May 7.

PMID:
24811743
20.

Retinopathy and CKD as predictors of all-cause and cardiovascular mortality: National Health and Nutrition Examination Survey (NHANES) 1988-1994.

Ricardo AC, Grunwald JE, Parvathaneni S, Goodin S, Ching A, Lash JP.

Am J Kidney Dis. 2014 Aug;64(2):198-203. doi: 10.1053/j.ajkd.2014.01.437. Epub 2014 Mar 19.

21.

Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.

Wang H, Cui XX, Goodin S, Ding N, Van Doren J, Du Z, Huang MT, Liu Y, Cheng X, Dipaola RS, Conney AH, Zheng X.

Oncol Rep. 2014 Feb;31(2):835-41. doi: 10.3892/or.2013.2885. Epub 2013 Nov 29.

22.

Enzalutamide for the treatment of castration-resistant prostate cancer.

Ha YS, Goodin S, DiPaola RS, Kim IY.

Drugs Today (Barc). 2013 Jan;49(1):7-13. doi: 10.1358/dot.2013.49.1.1910724. Review.

PMID:
23362491
23.

Cabozantinib in prostate cancer: the beginning of a precision paradigm?

Goodin S, DiPaola RS.

J Clin Oncol. 2013 Feb 1;31(4):401-3. doi: 10.1200/JCO.2012.46.6185. Epub 2012 Dec 17. No abstract available.

PMID:
23248244
24.

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.

Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS.

Med Sci Monit. 2012 Apr;18(4):CR260-4.

25.

Abiraterone in prostate cancer: a new angle to an old problem.

Stein MN, Goodin S, Dipaola RS.

Clin Cancer Res. 2012 Apr 1;18(7):1848-54. doi: 10.1158/1078-0432.CCR-11-1805. Epub 2012 Mar 26. Review.

26.

A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma.

Gounder MK, Lin H, Stein M, Goodin S, Bertino JR, Kong AN, DiPaola RS.

Biomed Chromatogr. 2012 May;26(5):650-4. doi: 10.1002/bmc.1710. Epub 2011 Sep 19.

27.

Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel.

Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, Patel RA, Schwartz R, Tamés MJ, Terkola R, Vadnais B, Wright D, Meier K.

J Oncol Pract. 2011 Jan;7(1):7-12.

28.

Inhibitory Effect of a γ-Tocopherol-Rich Mixture of Tocopherols on the Formation and Growth of LNCaP Prostate Tumors in Immunodeficient Mice.

Zheng X, Cui XX, Khor TO, Huang Y, Dipaola RS, Goodin S, Lee MJ, Yang CS, Kong AN, Conney AH.

Cancers (Basel). 2011 Sep 28;3(4):3762-72. doi: 10.3390/cancers3043762.

29.

Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study.

Suh DC, Powers CA, Barone JA, Shin H, Kwon J, Goodin S.

Res Social Adm Pharm. 2010 Sep;6(3):246-56. doi: 10.1016/j.sapharm.2009.07.004.

30.

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.

Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E, Dipaola RS.

Prostate. 2010 Sep 15;70(13):1388-94. doi: 10.1002/pros.21172.

31.

Ixabepilone, a new treatment option for metastatic breast cancer.

Toppmeyer DL, Goodin S.

Am J Clin Oncol. 2010 Oct;33(5):516-21. doi: 10.1097/COC.0b013e3181b9cd52. Review.

PMID:
20023567
32.

Management of venous thromboembolism and the potential to impact overall survival in patients with cancer.

Saraiya B, Goodin S.

Pharmacotherapy. 2009 Nov;29(11):1344-56. doi: 10.1592/phco.29.11.1344. Review.

PMID:
19857150
33.

Overcoming drug resistance in patients with metastatic breast cancer.

Wong ST, Goodin S.

Pharmacotherapy. 2009 Aug;29(8):954-65. doi: 10.1592/phco.29.8.954. Review.

PMID:
19637949
34.

Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats.

Strader AD, Clausen TR, Goodin SZ, Wendt D.

Obes Surg. 2009 Jan;19(1):96-104. doi: 10.1007/s11695-008-9754-x. Epub 2008 Nov 7.

PMID:
18989728
35.

Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.

Goodin S.

Am J Health Syst Pharm. 2008 Nov 1;65(21):2017-26. doi: 10.2146/ajhp070628. Review.

PMID:
18945860
36.

Effect of gonadectomy on AgRP-induced weight gain in rats.

Goodin SZ, Kiechler AR, Smith M, Wendt D, Strader AD.

Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R1747-53. doi: 10.1152/ajpregu.90345.2008. Epub 2008 Oct 15. Erratum in: Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1290. Keichler, Alicia R [corrected to Kiechler, Alicia R].

37.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
38.

Development of monoclonal antibodies for the treatment of colorectal cancer.

Goodin S.

Am J Health Syst Pharm. 2008 Jun 1;65(11 Suppl 4):S3-7; quiz S22-4. doi: 10.2146/ajhp080100.

PMID:
18499888
39.

Progress in the development of monoclonal antibody therapies for colorectal cancer. Introduction.

Goodin S.

Am J Health Syst Pharm. 2008 Jun 1;65(11 Suppl 4):S2. doi: 10.2146/ajhp080099. No abstract available.

PMID:
18499886
40.

Novel cytotoxic agents: epothilones.

Goodin S.

Am J Health Syst Pharm. 2008 May 15;65(10 Suppl 3):S10-5. doi: 10.2146/ajhp080089. Review.

PMID:
18463327
41.

Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns.

Georgy A, Neceskas J, Goodin S.

Am J Health Syst Pharm. 2007 Nov 1;64(21):2227-36. Review.

PMID:
17959573
42.

Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.

Nishioka J, Goodin S.

J Oncol Pharm Pract. 2007 Jun;13(2):85-97. Review.

PMID:
17873108
43.

Current issues associated with oral chemotherapy: a roundtable discussion.

Goodin S, Aisner J, Bartel SB, Viele CS.

Am J Health Syst Pharm. 2007 May 1;64(9 Suppl 5):S33-5. No abstract available.

PMID:
17468155
44.

Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions.

Goodin S.

Am J Health Syst Pharm. 2007 May 1;64(9 Suppl 5):S15-24. Review.

PMID:
17468152
45.

Clinical and biological activity of soy protein powder supplementation in healthy male volunteers.

Goodin S, Shen F, Shih WJ, Dave N, Kane MP, Medina P, Lambert GH, Aisner J, Gallo M, DiPaola RS.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):829-33.

46.

Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.

Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH.

Clin Cancer Res. 2006 Nov 1;12(21):6517-22. Epub 2006 Oct 25.

47.

Erlotinib: optimizing therapy with predictors of response?

Goodin S.

Clin Cancer Res. 2006 May 15;12(10):2961-3. No abstract available.

48.

Cancer-treatment-induced bone loss, part 2.

Michaud LB, Goodin S.

Am J Health Syst Pharm. 2006 Mar 15;63(6):534-46. Review.

PMID:
16522890
49.

Cancer-treatment-induced bone loss, part 1.

Michaud LB, Goodin S.

Am J Health Syst Pharm. 2006 Mar 1;63(5):419-30. Review.

PMID:
16484516
50.

Selecting an anticoagulant for recurrent venous thromboembolism in cancer.

Goodin S.

Am J Health Syst Pharm. 2005 Nov 15;62(22 Suppl 5):S10-3.

PMID:
16286363

Supplemental Content

Loading ...
Support Center